CA-PATIENT-SAFETY-MOVE
31.8.2021 14:02:09 CEST | Business Wire | Press release
The second annual #UniteForSafeCare event is scheduled for Friday, September 17th in conjunction with World Patient Safety Day. The event is hosted by the Patient Safety Movement Foundation (PSMF) and co-convened with The Leapfrog Group to bring global awareness to the lack of safety in healthcare and the fact that more than three million people die each year as the result of unsafe care. The event will explore how the public and other stakeholders can call for high reliability in healthcare, as well as the World Health Organization’s 2021 theme of “safe maternal and newborn care.”
As part of this year’s event, leadership from the Patient Safety Movement Foundation will coordinate demonstrations on both the east and west coasts in honor of World Patient Safety Day. Patient Safety Movement Foundation CEO Dr. David B. Mayer will continue his walk which began in February 2020 to raise awareness of patient and healthcare worker safety. Since starting, he has covered over 3,400 miles and been joined by families impacted by patient harm in over 30 states. This year’s walk will begin on September 11th on the 20th anniversary of the terrorist attacks to honor the lives lost and impacted, and will start in Gettysburg, Penn. Gettysburg was chosen as the starting point due to its strong visual representation of lives lost during the American Civil War drawing parallel to the lives lost each day due to unsafe care. The walk will finish in front of the White House in a call for action before continuing on to Capitol Hill.
“Over 8,220 people die every day in hospitals worldwide from unsafe care – that’s six people every minute – and the pandemic is making the delivery of safe care even harder,” stated Mayer. “This annual event allows us to bring the community and stakeholders together to raise awareness of this issue and advocate for change to make zero preventable deaths a reality.”
Here are the ways you can get involved this year:
- Attend the free virtual event: The virtual event will occur from 11 a.m. to 3:15 p.m. PDT on Friday, September 17th. At the event, attendees will have the chance to hear from Patient Safety Movement Foundation leadership, as well as over 20 speakers including Tedros Adhanom Ghebreyesus, PhD, MSc, director-general of the World Health Organization. Dariush Eghbali, an Iranian artist and humanitarian, will be performing and attendees will have the opportunity to network and access exhibitor booths. In addition, there will be a panel with the showrunner and cast of Peacock’s TV series “Dr. Death” followed by a segment to memorialize the patients we’ve lost due to preventable harm. Attendees will have the opportunity to bid on items up for auction – including a private screening and Q&A session with the filmmaker of HBO’s “Bleed Out,” as well as a conversation with Patrick Macmanus, the showrunner of “Dr. Death.” All proceeds of the auction support awareness and education initiatives. To see the full schedule and RSVP, visit: https://patient.sm/B15-UFSC .
- Host your own walk: Download the Charity Miles app and walk on your own or invite your coworkers and community to dedicate a walk, run, bike or any movement to show your support for the cause.
- Make a donation : Donations help fund awareness and education campaigns throughout the year. Individuals can make donations in honor of loved ones who have been affected by preventable medical harm. PSMF will plant an orange flag in Orange County or Washington D.C. for any donation of $10 or more. To help PSMF reach its goal of $250,000, visit: https://patient.sm/PR-UFSC-Donate .
- Share on social: Spread the word and help advocate for safer care by increasing awareness on social media. Use the hashtag #uniteforsafecare or translate it into any language to keep the conversation going globally.
- Send in your art: New this year, a virtual patient, family and survivor art gallery is available for individuals to share personal expressions of the emotions they felt as they navigated experiences with medical errors – whether it ended in tragedy or in joy. The art will be displayed along with a place to share the meaning behind the piece. To view the art or submit your own piece, visit: https://patient.sm/B15-Artwork .
- Wear and “light up” orange: Show your support by wearing orange, the official World Patient Safety Day color, or lighting up your house, a local monument or business orange. Share your photos on social media between September 13th and September 17th. You can also purchase official campaign t-shirts and hats: https://patient.sm/B15-Shop .
This year’s event is made possible by the generous sponsorship of Dr. Steven J. Barker, Gordon & Betty Moore Foundation, HealthySimulation.com, Jewish Healthcare Foundation, Josie King Foundation, Kaiser Permanente, Liamar Healthcare, Medstar Health Institute for Quality and Safety and Teletracking. To learn more about #UniteForSafeCare, visit: https://patientsafetymovement.org/unite-for-safe-care/home/ .
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005375/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
